Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 557 participants.

Also called NCT01758380

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 557 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01758380
  • EudraCT 2011-005499-41
Other papers using this trial's data
  • A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study Vascular health and risk management, 2014 DOI, PubMed 24920915, PMC4045264 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Denmark, Egypt, Germany, Indonesia, Jordan, Kuwait, Lebanon, Malaysia, Russia, Saudi Arabia, Singapore, Spain, Tunisia, Türkiye, United Arab Emirates, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01758380. Randomized; quadruple masking; primary purpose treatment. Start 2013-01 (registry gives no type); primary completion 2013-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan
Acronym
STEADFAST
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Vildagliptin
Intervention (Drug)
Gliclazide
Intervention (Drug)
Metformin
Intervention (Drug)
Placebo to Gliclazide
Intervention (Drug)
Placebo to Vildagliptin
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01758380
Content hash
2ee90b6228226fa5962b3e2ebc35a37f18bb9fdc79708895b85ab04b177332f7